Antitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: A meta-analysis

Critical Care Medicine

Volumn 41, Issue 10, 2013, Pages 2419-2429

  Qiu, Ping ^a   Cui, Xizhong ^a   Sun, Junfeng ^a   Welsh, Judith ^a   Natanson, Charles ^a   Eichacker, Peter Q ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

sepsis; septic shock; treatment; tumor necrosis factor

Indexed keywords

AFELIMOMAB; BAYX 1351; CA 2; CB 006; CYTOFAB; MAK 195F; MONOCLONAL ANTIBODY BAYX 1351; MONOCLONAL ANTIBODY CA2; MONOCLONAL ANTIBODY CB 006; MONOCLONAL ANTIBODY MAK 195F; PLACEBO; PROTEIN P55; PROTEIN P75; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; DEATH; HUMAN; INTERVENTION STUDY; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SECONDARY INFECTION; SEPSIS; SURVIVAL; SURVIVAL RATE; THERAPY EFFECT;

ANTIBODIES, MONOCLONAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEPSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84884887658     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3182982add     Document Type: Review

References (33)

1. Thalayasingam N, Isaacs JD: Anti-TNF therapy. Best Pract Res Clin Rheumatol 2011; 25:549-567
2. Abraham E, Wunderink R, Silverman H, et al: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995; 273:934-941
3. Cohen J, Carlet J: INTERSEPT: An international, multicenter, placebo- controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24:1431-1440 (Pubitemid 26313741)
4. Abraham E, Anzueto A, Gutierrez G, et al: Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998; 351:929-933 (Pubitemid 28138465)
5. Fisher CJ Jr, Opal SM, Dhainaut JF, et al: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med 1993; 21:318-327 (Pubitemid 23097025)
6. Reinhart K, Wiegand-Löhnert C, Grimminger F, et al: Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996; 24:733-742
7. Dhainaut JF, Vincent JL, Richard C, et al: CDP571, a humanized antibody to human tumor necrosis factor-alpha: Safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Crit Care Med 1995; 23:1461-1469
8. Clark MA, Plank LD, Connolly AB, et al: Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis-a randomized, clinical trial. Crit Care Med 1998; 26:1650-1659 (Pubitemid 28467672)
9. Abraham E, Glauser MP, Butler T, et al: p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 1997; 277:1531-1538 (Pubitemid 27213302)
10. Fisher CJ Jr, Agosti JM, Opal SM, et al: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334:1697-1702 (Pubitemid 26193621)
11. Beutler B, Milsark IW, Cerami AC: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229:869-871 (Pubitemid 16246587)
12. Qiu P, Cui X, Barochia A, et al: The evolving experience with therapeutic TNF inhibition in sepsis: Considering the potential influence of risk of death. Expert Opin Investig Drugs 2011; 20:1555-1564
13. Wenzel RP: Treating sepsis. N Engl J Med 2002; 347:966-967
14. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310 (Pubitemid 32641789)
15. Marshall JC: Such stuff as dreams are made on: Mediator-directed therapy in sepsis. Nat Rev Drug Discov 2003; 2:391-405 (Pubitemid 37361709)
16. Natanson C, Esposito CJ, Banks SM: The sirens' songs of confirmatory sepsis trials: Selection bias and sampling error. Crit Care Med 1998; 26:1927-1931 (Pubitemid 29016658)
17. Reinhart K, Karzai W: Anti-tumor necrosis factor therapy in sepsis: Update on clinical trials and lessons learned. Crit Care Med 2001; 29(7 Suppl):S121-S125 (Pubitemid 32681594)
18. Morris PE, Zeno B, Bernard AC, et al: A placebo-controlled, double- blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock. Crit Care 2012; 16:R31
19. Panacek EA, Marshall JC, Albertson TE, et al; Monoclonal Anti-TNF: A Randomized Controlled Sepsis Study Investigators: Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32:2173-2182 (Pubitemid 39491795)
20. Rice TW, Wheeler AP, Morris PE, et al: Safety and efficacy of affinity- purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis. Crit Care Med 2006; 34:2271-2281 (Pubitemid 44260009)
21. Bone RC, Balk RA, Cerra FB, et al; ACCP/SCCM Consensus Conference Committee: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/ SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest 2009; 136(5 Suppl):e28
22. Jadad AR, Moore RA, Carroll D, et al: Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996; 17:1-12 (Pubitemid 26120810)
23. Gallagher J, Fisher C, Sherman B, et al: A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-alpha antibody afelimomab in patients with sepsis syndrome. Intensive Care Med 2001; 27:1169-1178 (Pubitemid 32710204)
24. Reinhart K, Menges T, Gardlund B, et al: Randomized, placebocontrolled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES study. Crit Care Med 2001; 29:765-769 (Pubitemid 32299714)
25. Abraham E, Laterre PF, Garbino J, et al; Lenercept Study Group: Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001; 29:503-510 (Pubitemid 32225290)
26. Levy MM, Artigas A, Phillips GS, et al: Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: A prospective cohort study. Lancet Infect Dis 2012; 12:919-924
27. Angus D, Kellum JA, Yealy DM: Protocolized care for early septic shock (ProCESS). Available at: http://www.clinicaltrials.gov/ct2/show/NCT00510835? term=ProCESS&rank=1. Accessed January 14, 2013
28. Minneci PC, Deans KJ, Eichacker PQ, et al: The effects of steroids during sepsis depend on dose and severity of illness: An updated meta-analysis. Clin Microbiol Infect 2009; 15:308-318
29. Lorente JA, Marshall JC: Neutralization of tumor necrosis factor in preclinical models of sepsis. Shock 2005; 24(Suppl 1):107-119
30. Eichacker PQ, Parent C, Kalil A, et al: Risk and the efficacy of antiinflammatory agents: Retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002; 166:1197-1205 (Pubitemid 35222596)
31. Knaus WA, Harrell FE Jr, LaBrecque JF, et al: Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-1ra Phase III Sepsis Syndrome Study Group. Crit Care Med 1996; 24:46-56
32. BTG kills AZD9773 development. Available at: http://www.dddmag.com/news/ 2012/08/btg-kills-azd9773-development. Accessed January 13, 2013
33. Bernard G, Botnick W, Lindemann J, et al: A study to compare the efficacy and safety of 2 dosing regimens of IV infusions of AZD9773 (CytoFab™) with placebo in adult patients with severe sepsis and/or septic shock. Available at: http://clinicaltrial.gov/ct2/show/NCT01145560?term=NCT01145560&rank=1. Accessed January 13, 2013